“Growing Adoption of ECMO Therapy”
One significant trend in the acute respiratory distress syndrome (ARDS) market is the growing adoption of extracorporeal membrane oxygenation (ECMO) therapy as an advanced life-support intervention for severe ARDS cases. ECMO provides prolonged cardiac and respiratory support for patients with extreme lung failure when conventional ventilation methods are insufficient. The increasing prevalence of ARDS, particularly in critically ill COVID-19 patients, has accelerated the demand for ECMO systems in intensive care units (ICUs) worldwide. For instance, during the pandemic, leading hospitals in the U.S. and Europe expanded their ECMO programs to improve survival rates for ARDS patients. In addition, advancements in portable ECMO devices have enabled better patient mobility and reduced complications associated with long-term ventilation. With ongoing research into optimizing ECMO protocols and integrating artificial intelligence (AI) for real-time monitoring, the ARDS market is witnessing a shift toward more effective, technology-driven treatment approaches to enhance patient outcomes.
